U.S. Bio Company Executives Cash Out Millions in Stock Options

At United Therapeutics Corp. (UTHR), a U.S. biotech firm, Chair and CEO Martine Rothblatt and CFO James Edgemond exercised stock options on March 20 and 23, respectively, and sold the shares on the same day in the open market—each realizing gains of several million dollars (equivalent to tens of billions of Korean won). CEO Rothblatt acquired common shares at exercise prices in the low-$140 range and sold them at $520–$530, capturing a substantial spread. CFO Edgemond likewise exercised options with strike prices in the low-$130 range and disposed of the shares at $510–$530, achieving comparable profits.

Following these transactions, both executives’ direct and indirect holdings declined somewhat. Nonetheless, disclosures indicate that CEO Rothblatt still holds several hundred thousand shares through family trusts, while CFO Edgemond retains a stake valued at approximately $10 million (around ₩10 billion).

The company has also continued to deliver positive pipeline news on both clinical and regulatory fronts. On April 8, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to its artificial-liver platform candidate, miroliverELAP, for treating acute liver failure. At the end of March, United Therapeutics announced that Tyvaso, its idiopathic pulmonary fibrosis treatment candidate, met the primary endpoint in the Phase 3 TETON-1 trial—another favorable development in its pipeline. ()

Headquartered in Maryland and North Carolina, United Therapeutics develops and markets therapies for rare and serious pulmonary diseases—such as pulmonary arterial hypertension and pulmonary fibrosis—as well as treatments related to organ transplantation. The company has six FDA-approved products, including Tyvaso, Remodulin, and Orenitram, and generated approximately $2.3 billion (about ₩3 trillion) in revenue in 2023. ()